Desmoid tumor: From surgical extirpation to molecular dissection

Current Opinion in Oncology

Volumn 21, Issue 4, 2009, Pages 352-359

  Lazar, Alexander J F ^a   Hajibashi, Shohrae ^a   Lev, Dina ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CTNN; Desmoid fibromatosis; Mutations; P catenin; Prognosis

Indexed keywords

BETA CATENIN; HORMONE ANTAGONIST; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN;

BREAST ADENOCARCINOMA; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ASSESSMENT; COLON ADENOCARCINOMA; COLORECTAL CANCER; CRANIOPHARYNGIOMA; DESMOID TUMOR; DISEASE COURSE; DISSECTION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; GENE MUTATION; GENOTYPE; HEPATOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MELANOMA; MICROSCOPY; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PILOMATRIXOMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RETROSPECTIVE STUDY; REVIEW; SKIN CANCER; SMALL INTESTINE CARCINOMA; STOMACH ADENOCARCINOMA; SYNOVIAL SARCOMA; THYROID CANCER; TREATMENT RESPONSE; FIBROMATOSIS; GENETICS; MESENCHYMOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

BETA CATENIN; COMBINED MODALITY THERAPY; FIBROMATOSIS, AGGRESSIVE; HUMANS; MESENCHYMOMA; WNT PROTEINS;

EID: 67650309546     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832c9502     Document Type: Review

References (52)

1. Kotiligam D, Lazar AJ, Pollock RE, Lev D. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 2008; 23:117-126.
2. Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25:1785-1791.
3. Melis M, Zager JS, SondakVK. Multimodality management of desmoid tumors: how important is a negative surgical margin? J Surg Oncol 2008; 98:594-602.
4. Heinrich MC, McArthurGA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24:1195-1203.
5. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999; 17:158-167.
6. Guadagnolo BA, Zagars GK, Ballo MT. Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 2008; 71:441 -447.
7. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008; 14:2717 -2725.
8. Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 2006; 24:11 -12.
9. Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24:102 -105.
10. Patel SR, Evans HL, Benjamin RS.combination chemotherapy in adult desmoid tumors. Cancer 1993; 72:3244-3247.
11. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with metho- trexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92:1259 -1264.
12. Okuno S. The enigma of desmoid tumors. Curr Treat Options Oncol 2006; 7:438-443.
13. Stoeckle E, Coindre JM, Longy M, et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol 2009; 35:129 -134.
14. Shido Y, Nishida Y, Nakashima H, et al. Surgical treatment for local control of extremity and trunk desmoid tumors. Arch Orthop Trauma Surg 2008 [Epub ahead of print].
15. Nakayama T, Tsuboyama T, Toguchida J, et al. Natural course ofdesmoid-type fibromatosis. J Orthop Sci 2008; 13:51 -55.
16. Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibroma- tosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34:462 -468.
17. Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998; 40:637-645.
18. Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999; 86:2045-2052.
19. Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra- abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003; 21:1390-1397.
20. Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg 1999; 229:866 -872; discussion 872-873.
21. Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14:181 -190.
22. Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer 2006; 106: 208-213.
23. Liegl B, Leithner A, Bauernhofer T, et al. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours? Histopathology 2006; 49:576-581.
24. Jelinek JA, Stelzer KJ, Conrad E, et al. The efficacy of radiotherapy as postoperative treatment for desmoid tumors. Int J Radiat Oncol Biol Phys 2001; 50:121-125.
25. Barker N. The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol 2008; 468:5-15.
26. Sen-Gupta S, Van der Luijt RB, Bowles LV, et al. Somatic mutation of APC gene in desmoid tumour in familial adenomatous polyposis. Lancet 1993; 342:552-553.
27. Alman BA, Li C, Pajerski ME, et al. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151:329 -334.
28. Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol 1998; 153:709 -714.
29. Miyoshi Y, Iwao K, NawaG, et al. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res 1998; 10:591 -594.
30. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999; 18:6615-6620.
31. Saito T, Oda Y, Tanaka K, et al. Beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. J Pathol 2001; 195:222 -228.
32. Abraham SC, Reynolds C, Lee JH, et al. Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol 2002; 33:39-46.
33. Amary MF, Pauwels P, Meulemans E, et al. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation- specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am J Surg Pathol 2007; 31:1299-1309.
34. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008; 173:1518 -1527.
35. Lazar AJ, Trent JC, Lev D. Sarcoma molecular testing: diagnosis and prognosis. Curr Oncol Rep 2007; 9:309-315.
36. Oliveira AM, Fletcher CD. Molecular prognostication for soft tissue sarcomas: Are we ready yet? J Clin Oncol 2004; 22:4031 -4034.
37. Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin 2006; 56:282 -291; quiz 314-315.
38. Chien AJ, Moore EC, LonsdorfAS, et al. Activated Wnt/ss-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 2009; 106:1193-1198.
39. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005; 18 (Suppl 2):S19 -S32.
40. Oliva E, Sarrio D, Brachtel EF, et al. High frequency ofbeta-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol 2006; 208:708-713.
41. Irving JA, Catasus L, Gallardo A, et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 2005; 36:605-619.
42. Johnson V, Volikos E, Halford SE, et al. Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary nonpolyposis colorectal cancer syndrome. Gut 2005; 54:264-267.
43. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endome- trial carcinomas irrespective of mutator pathway. Cancer Res 1999; 59:3346-3351.
44. Rowley PT. Inherited susceptibility to colorectal cancer. Annu Rev Med 2005; 56:539-554.
45. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17:45-51.
46. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008; 27:6920-6929.
47. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005; 18:68 -74.
48. Iwao K, Miyoshi Y, Nawa G, et al. Frequent beta-catenin abnormalities in bone and soft-tissue tumors. Jpn J Cancer Res 1999; 90:205-209.
49. Saito T, Oda Y, Sakamoto A, et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 2000; 192:342-350.
50. Zhang DL, Gu LJ, Liu L, et al. Effect of Wnt signaling pathway on wound healing. Biochem Biophys Res Commun 2009; 378:149-151.
51. Takahashi-Yanaga F, Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 2007; 104:293-302.
52. Takemaru KI, Ohmitsu M, Li FQ. An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics. Handb Exp Pharmacol 2008; (186):261-284.